Abu Dhabi has taken a decisive step toward turning genomic research into life‑saving treatments. The Department of Health – Abu Dhabi (DoH) announced three new agreements today that will strengthen the emirate’s gene‑editing ecosystem, from discovery to patient care.
Partnerships that span the entire pipeline
The first agreement links DoH with Children’s Hospital of Philadelphia (CHOP). The MoU focuses on rare disease care and gene‑editing techniques for conditions such as liver metabolic disorders, genetic clotting disorders, urea cycle disorders and central nervous system conditions. By sharing expertise, the two institutions aim to refine innovative approaches that could bring new therapies to patients in the region.
DoH’s second collaboration is with Mammoth Biosciences, a company known for its CRISPR‑based diagnostics. Together, they will advance gene‑editing therapies, clinical research and advanced therapy manufacturing. The partnership will also tap into insights generated through the Emirati Genome Program, which supplies population‑scale genomic data that helps identify disease prevalence and targets for treatment.
The third agreement brings Arbor Biotechnologies into the fold. While the details of the collaboration are still being finalized, the partnership will support the development of gene‑editing therapies and strengthen the emirate’s manufacturing capabilities for advanced treatments.
Building on a strong genomic foundation
Abu Dhabi’s unique advantage lies in its combination of a large population genomics programme, integrated healthcare infrastructure, advanced research facilities and a supportive regulatory environment. The Emirati Genome Program has already mapped genetic variations across the emirate’s population, providing a powerful resource for identifying rare and inherited diseases early.
With the new agreements in place, the emirate is poised to move from data collection to therapeutic development. The collaborations will bring together clinical research, scientific expertise, advanced therapeutics and future manufacturing, creating a connected ecosystem that can accelerate the journey from genomic discovery to patient impact.
DoH’s strategy reflects a broader vision to transform Abu Dhabi into a hub for intelligent life sciences. By integrating research, healthcare, regulation, investment and innovation, the emirate aims to improve outcomes for patients with rare and inherited conditions and to position itself at the forefront of next‑generation therapies.
Looking ahead
While the agreements are a significant milestone, the journey ahead involves rigorous clinical trials, regulatory approvals and scaling of manufacturing processes. The partnerships with CHOP, Mammoth Biosciences and Arbor Biotechnologies will play a crucial role in navigating these stages and ensuring that gene‑editing therapies reach patients safely and effectively.
As Abu Dhabi continues to invest in its life‑sciences ecosystem, the focus remains on translating scientific breakthroughs into tangible health benefits. The new agreements underscore the emirate’s commitment to harnessing genomics for the betterment of its population and to setting a benchmark for innovation in the region.
Frequently asked questions
What are the new gene‑editing agreements signed by Abu Dhabi?
Abu Dhabi’s Department of Health signed three agreements with Children’s Hospital of Philadelphia, Mammoth Biosciences and Arbor Biotechnologies to accelerate development, testing and future manufacturing of gene‑editing therapies for rare and inherited diseases.
Which institutions is Abu Dhabi partnering with for gene‑editing therapies?
The partnerships are with Children’s Hospital of Philadelphia (CHOP), the CRISPR‑diagnostics company Mammoth Biosciences, and gene‑editing specialist Arbor Biotechnologies.
What rare diseases are targeted by the Abu Dhabi‑CHOP collaboration?
The MoU with CHOP focuses on liver metabolic disorders, genetic clotting disorders, urea cycle disorders and central nervous system conditions.
How does the Emirati Genome Program support the new gene‑editing collaborations?
The program provides population‑scale genomic data that identifies disease prevalence and therapeutic targets, feeding insights into the partnerships with Mammoth Biosciences and others.
Will the agreements help the UAE manufacture gene‑editing treatments locally?
Yes, the deals aim to strengthen the emirate’s manufacturing capabilities for advanced therapies, especially through the collaboration with Arbor Biotechnologies and the advanced therapy manufacturing component of the Mammoth partnership.
